Cooperative Treatment of Gastric Cancer Using B7-H7 siRNA and Docetaxel; How Could They Modify Their Effectiveness?
B7-H7
Chemo-sensitivity
Combination therapy
Docetaxel
Gastric cancer
siRNA
Journal
Advanced pharmaceutical bulletin
ISSN: 2228-5881
Titre abrégé: Adv Pharm Bull
Pays: Iran
ID NLM: 101578021
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
27
02
2022
revised:
04
04
2022
accepted:
01
07
2022
medline:
30
8
2023
pubmed:
30
8
2023
entrez:
30
8
2023
Statut:
ppublish
Résumé
Despite the high prevalence of gastric cancer (GC), drug resistance is a major problem for effective chemotherapy. B7-H7 is a novel member of the B7 superfamily and is expressed in most common cancers. However, the role of B7-H7 on the aggressiveness of GC and chemosensitivity has remained unknown. Therefore, this study was designed to assess the effect of B7-H7 suppression using small interference RNA (siRNA) in combination with docetaxel on GC cells. MTT test was applied to determine the IC50 of docetaxel and the combined effect of B7-H7 siRNA and docetaxel on the viability of the MKN-45 cells. To determine B7-H7, BCL-2, BAX, and caspase-3-8-9 genes expression, qRT-PCR was performed. Furthermore, flow cytometry was applied to evaluate apoptosis and the cell cycle status. Finally, to evaluate the effect of this combination therapy on migratory capacity and colony-forming ability, wound healing assay and colony formation test were employed, respectively. B7-H7 suppression increased the chemo-sensitivity of MKN-45 cells to docetaxel. The expression of B7-H7 mRNA was reduced after using B7-H7 siRNA and docetaxel in MKN-45 GC cells. Also, B7-H7 suppression alongside docetaxel reduced cell migration and colony formation rate, arrested the cell cycle at the G2-M phase, and induced apoptosis by modulating the expression of apoptotic target genes. B7-H7 plays a significant role in the chemo-sensitivity and pathogenesis of GC. Therefore, B7-H7 suppression, in combination with docetaxel, may be a promising therapeutic approach in treating GC.
Identifiants
pubmed: 37646055
doi: 10.34172/apb.2023.055
pmc: PMC10460818
doi:
Types de publication
Journal Article
Langues
eng
Pagination
573-582Informations de copyright
©2023 The Authors.
Déclaration de conflit d'intérêts
The authors declare that there is no conflict of interest related to this study.
Références
Adv Pharm Bull. 2017 Sep;7(3):339-348
pubmed: 29071215
Nat Commun. 2013;4:2043
pubmed: 23784006
Adv Pharm Bull. 2014 Dec;4(4):313-21
pubmed: 25436185
Anticancer Agents Med Chem. 2016;16(3):318-34
pubmed: 26234359
Sci Rep. 2019 Oct 16;9(1):14854
pubmed: 31619714
Clin Cancer Res. 2015 May 15;21(10):2359-66
pubmed: 25549724
Ecancermedicalscience. 2018 Nov 26;12:883
pubmed: 30679950
Cancer Cell Int. 2019 Apr 16;19:101
pubmed: 31015801
Clin Cancer Res. 2017 Feb 1;23(3):825-832
pubmed: 27553831
Nat Rev Mol Cell Biol. 2007 May;8(5):379-93
pubmed: 17426725
J Med Genet. 2019 Jan;56(1):43-49
pubmed: 29967134
Oncol Lett. 2018 Jul;16(1):91-96
pubmed: 29963127
Int J Oncol. 2016 Apr;48(4):1561-70
pubmed: 26891663
Onco Targets Ther. 2018 Mar 20;11:1563-1570
pubmed: 29593422
Proc Natl Acad Sci U S A. 2013 Jun 11;110(24):9879-84
pubmed: 23716685
Biomed Pharmacother. 2021 May;137:111364
pubmed: 33592546
Mol Cancer Ther. 2017 Jul;16(7):1203-1211
pubmed: 28679835
Immune Netw. 2014 Dec;14(6):265-76
pubmed: 25550693
Nephron. 2019;141(4):256-264
pubmed: 30602154
Oncol Rep. 2007 Aug;18(2):329-36
pubmed: 17611652
Oncotarget. 2017 Jun 6;8(23):38022-38043
pubmed: 28410237
Nat Rev Immunol. 2008 Jun;8(6):467-77
pubmed: 18500231
Hum Cell. 2020 Jan;33(1):116-122
pubmed: 31552567
Exp Cell Res. 2018 Jan 15;362(2):525-531
pubmed: 29269075
Int J Mol Sci. 2020 Jun 04;21(11):
pubmed: 32512697
Sci Rep. 2016 Aug 17;6:31154
pubmed: 27531281
Mol Cancer Ther. 2011 Jun;10(6):960-71
pubmed: 21518725
Oncoimmunology. 2015 Apr 14;4(8):e1026534
pubmed: 26405587
Oncotarget. 2017 Jun 6;8(23):37435-37447
pubmed: 28415577
Clin Cancer Res. 2018 Apr 15;24(8):1954-1964
pubmed: 29374053
Sci Rep. 2019 Apr 9;9(1):5839
pubmed: 30967582